BACKGROUND: Hyperprothrombinemia, resulting from the prothrombin G20210A mutation or other causes, is associated with activated protein C (APC) resistance and increased thrombosis risk. When high prothrombin levels are a result of increased hepatic biosynthesis, these effects may be counteracted by concomitantly increased levels of the anticoagulant factors (particularly protein S). Differently, in prothrombin G20210A carriers only prothrombin levels are elevated. OBJECTIVE: To investigate whether prothrombin G20210A carriers have a more severe hypercoagulable state than non-carriers with comparable prothrombin levels. PATIENTS/ METHODS: Coagulation factor levels, thrombin generation (Calibrated Automated Thrombogram in the presence and absence of APC) and APC resistance were measured in normal (n = 132), heterozygous (n = 167) and homozygous (n = 3) individuals. RESULTS: Prothrombin levels, thrombin generation and APC resistance were higher in carriers of the prothrombin G20210A mutation (especially those who had experienced venous thrombosis) than in non-carriers, whereas protein S and antithrombin levels were similar among genotype groups. Because individuals with high prothrombin levels in the absence of the prothrombin G20210A mutation tend to have all liver-synthesized factors elevated, carriers of the mutation had lower protein S and antithrombin levels than non-carriers with equally high prothrombin levels. Accordingly, they also generated more thrombin and showed a tendency toward higher APC resistance. Analogous effects, but less pronounced, were observed in homozygotes for the prothrombin A19911G polymorphism, which also upregulates prothrombin levels. CONCLUSIONS: Individuals with hyperprothrombinemia as a result of prothrombin gene mutations generate more thrombin and tend to be more APC-resistant than individuals with comparable prothrombin levels because of other causes.
BACKGROUND:Hyperprothrombinemia, resulting from the prothrombinG20210A mutation or other causes, is associated with activated protein C (APC) resistance and increased thrombosis risk. When high prothrombin levels are a result of increased hepatic biosynthesis, these effects may be counteracted by concomitantly increased levels of the anticoagulant factors (particularly protein S). Differently, in prothrombinG20210A carriers only prothrombin levels are elevated. OBJECTIVE: To investigate whether prothrombinG20210A carriers have a more severe hypercoagulable state than non-carriers with comparable prothrombin levels. PATIENTS/ METHODS: Coagulation factor levels, thrombin generation (Calibrated Automated Thrombogram in the presence and absence of APC) and APC resistance were measured in normal (n = 132), heterozygous (n = 167) and homozygous (n = 3) individuals. RESULTS:Prothrombin levels, thrombin generation and APC resistance were higher in carriers of the prothrombinG20210A mutation (especially those who had experienced venous thrombosis) than in non-carriers, whereas protein S and antithrombin levels were similar among genotype groups. Because individuals with high prothrombin levels in the absence of the prothrombinG20210A mutation tend to have all liver-synthesized factors elevated, carriers of the mutation had lower protein S and antithrombin levels than non-carriers with equally high prothrombin levels. Accordingly, they also generated more thrombin and showed a tendency toward higher APC resistance. Analogous effects, but less pronounced, were observed in homozygotes for the prothrombinA19911G polymorphism, which also upregulates prothrombin levels. CONCLUSIONS: Individuals with hyperprothrombinemia as a result of prothrombin gene mutations generate more thrombin and tend to be more APC-resistant than individuals with comparable prothrombin levels because of other causes.
Authors: F Yesim K Demirci; Amy S Dressen; Candace M Kammerer; M Michael Barmada; Amy H Kao; Rosalind Ramsey-Goldman; Susan Manzi; M Ilyas Kamboh Journal: J Rheumatol Date: 2011-01-15 Impact factor: 4.666
Authors: Maria M Aleman; Bethany L Walton; James R Byrnes; Jian-Guo Wang; Matthew J Heisler; Kellie R Machlus; Brian C Cooley; Alisa S Wolberg Journal: Arterioscler Thromb Vasc Biol Date: 2013-05-30 Impact factor: 8.311
Authors: Sherif Elkattawy; Ramez Alyacoub; Kerry S Singh; Hardik Fichadiya; William Kessler Journal: J Investig Med High Impact Case Rep Date: 2022 Jan-Dec
Authors: Charles L Percy; Rudolf Hartmann; Rhidian M Jones; Subramaniam Balachandran; Dheeraj Mehta; Michael Dockal; Friedrich Scheiflinger; Valerie B O'Donnell; Judith E Hall; Peter W Collins Journal: Blood Coagul Fibrinolysis Date: 2015-06 Impact factor: 1.276
Authors: Rita Carolina Figueiredo Duarte; Cláudia Natália Ferreira; Danyelle Romana Alves Rios; Helton José Dos Reis; Maria das Graças Carvalho Journal: Rev Bras Hematol Hemoter Date: 2017-05-09